Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Van Buren G 2nd, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, Moser AJ. Van Buren G 2nd, et al. Among authors: ramanathan rk. Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1. Ann Surg Oncol. 2013. PMID: 23904005 Clinical Trial.
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N. Carneiro BA, et al. Among authors: ramanathan rk. Clin Colorectal Cancer. 2012 Mar;11(1):53-9. doi: 10.1016/j.clcc.2011.05.003. Epub 2011 Aug 2. Clin Colorectal Cancer. 2012. PMID: 21813336 Clinical Trial.
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Sehgal R, Lembersky BC, Rajasenan KK, Crandall TL, Balaban EP, Pinkerton RA, Kane P, Schmotzer A, Zeh H, Potter DM, Ramanathan RK. Sehgal R, et al. Among authors: ramanathan rk. Clin Colorectal Cancer. 2011 Jun;10(2):117-20. doi: 10.1016/j.clcc.2011.03.008. Epub 2011 Apr 28. Clin Colorectal Cancer. 2011. PMID: 21859564 Clinical Trial.
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC. Ramanathan RK, et al. Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27. Cancer Chemother Pharmacol. 2005. PMID: 15723261 Clinical Trial.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Von Hoff DD, et al. Among authors: ramanathan rk. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16. N Engl J Med. 2013. PMID: 24131140 Free PMC article. Clinical Trial.
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD. Picozzi VJ, et al. Among authors: ramanathan rk. Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14. Eur J Cancer. 2015. PMID: 26187510 Free article. Clinical Trial.
226 results